Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.

Also called NCT01939496

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 171 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01939496
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01939496. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-04 (actual). Results posted on 2016-04-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Condition
Diabetes Mellitus, Type 2
Condition
Hypertension
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Janssen Scientific Affairs, LLC (class: industry)

Record details

Record id
cardio:ct-nct01939496
Content hash
bc75cb672958cd6dbb554501368ca601b5b5c722b42731b01e81d2622d2e8f80